Pear Therapeutics extends gain after LJ10 LLC disclosed stake. Pear recently closed its business combination with SPAC Thimble Point Acquisition. The combined company, Pear Therapeutics (PEAR), began trading on NASDAQ. The transaction was expected to generate about $175M in gross proceeds.

The rapidly emerging PDT category is building momentum with accelerating clinical validation, patient adoption, prescriber utilization, and payor reimbursement. This is a buy and hold! With this little float i will fly then!$Pear Therapeutics(PEAR)$

免责声明:上述内容仅代表发帖人个人观点,不构成本平台的任何投资建议。

举报

评论

  • 推荐
  • 最新
empty
暂无评论